Lupin Ltd — Capital/Financing Update 2018

Nov 26, 2018

BLOOMBERG: LPCIN

==> picture [169 x 32] intentionally omitted <==

----- Start of picture text ----- Press Release----- End of picture text -----

==> picture [45 x 53] intentionally omitted <==

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO

Lupin receives FDA approval for KCl for Oral Solution 20 mEq

Mumbai, Baltimore, November 26, 2018 : Pharma major Lupin announced that it has received approval for its Potassium Chloride for Oral Solution USP, 20 mEq from the United States Food and Drug Administration (FDA) to market a generic version of Pharma Research Software Solution LLC’s Potassium Chloride for Oral Solution, 20 mEq.

Lupin’s Potassium Chloride for Oral Solution USP, 20 mEq is the generic version of Pharma Research Software Solution, LLC’s Potassium Chloride for Oral Solution, 20 mEq. It is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient.

Potassium Chloride for Oral Solution USP, 20 mEq had annual sales of approximately USD 105 million in the US (IQVIA MAT September 2018).

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 13[th] largest generics pharmaceutical company in terms of market capitalization (30[th] September 2018, Bloomberg) and the 8[th] largest generics pharmaceutical company in terms of revenues (30[th] June 2018, Bloomberg LTM) globally. The Company is the 3[rd] largest pharmaceutical player in the US by prescriptions for the Total Market (IQVIA MAT September 2018); 3[rd] largest Indian pharmaceutical company by global revenues (30[th] June 2018, Bloomberg LTM); 6[th] largest generic pharmaceutical player in Japan (IQVIA MAT September 2018) and 5[th] largest company in the Indian Pharmaceutical Market (IQVIA MAT September 2018).

For the financial year ended 31[st] March, 2018, Lupin’s Consolidated sales and Net profits before exceptional items were at Rs. 155,598 million (USD 2.41 billion) and Rs. 13,934 million (USD 216 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinglobal

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

For further information or queries please contact –

Pooja Thakran VP – Corporate Communications Email: poojathakran@lupin.com Ph: +91-22-66402531 / 8291013225

Arvind Bothra Head – Investor Relations Email: arvindbothra@lupin.com Ph: +91-22-66402137

*Safe Harbor Statement